What price ranges applied to Brian Daniel Webster’s KMTS share sales?

The filing notes that reported prices are weighted averages over ranges. One tranche ranged from $25.0150 to $26.0100, another from $26.0200 to $26.9998, and the final from $27.0771 to $27.1800, with detailed breakdowns available on request to the issuer or SEC staff.

Kestra Medical director sells 15,000 KMTS shares

Kestra Medical Technologies director and officer Brian Daniel Webster sold a total of 15,000 Common Shares of KMTS in open-market transactions on February 17, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kestra Medical Technologies director and officer Brian Daniel Webster sold a total of 15,000 Common Shares of KMTS in open-market transactions on February 17, 2026. The sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025.

The transactions were executed in three tranches: 11,635 shares at a weighted average price of $25.3937, 3,272 shares at $26.2947, and 93 shares at $27.1789. After these sales, Webster directly held 379,786 Common Shares.

Insider Trade Summary

Net Seller: 15,000 shares

Net Sell 3 txns

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($384K)

Type	Security	Shares	Price	Value
Sale	Common Shares	11,635	$25.3937	$295K
Sale	Common Shares	3,272	$26.2947	$86K
Sale	Common Shares	93	$27.1789	$3K

Holdings After Transaction: Common Shares — 379,786 shares (Direct)

Footnotes (4)

F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0150 to $26.0100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.0200 to $26.9998. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.0771 to $27.1800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the KMTS Form 4 filing report for Brian Daniel Webster?

The Form 4 reports that Brian Daniel Webster, a director and officer of Kestra Medical Technologies (KMTS), sold 15,000 Common Shares on February 17, 2026, in open-market transactions executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.

How many Kestra Medical (KMTS) shares did Brian Daniel Webster sell and at what prices?

Brian Daniel Webster sold a total of 15,000 KMTS Common Shares in three tranches. He sold 11,635 shares at a weighted average price of $25.3937, 3,272 shares at $26.2947, and 93 shares at $27.1789, with each tranche executed across price ranges disclosed in the footnotes.

How many KMTS shares does Brian Daniel Webster own after the reported sales?

After the reported open-market sales on February 17, 2026, Brian Daniel Webster directly owns 379,786 Kestra Medical Technologies Common Shares. Each transaction line in the filing shows updated share balances, with the final reported total shares following the last sale listed as 379,786.

Was the KMTS insider sale by Brian Daniel Webster under a Rule 10b5-1 plan?

Yes. The filing states that the reported transactions occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. Such plans allow insiders to pre-schedule trades, providing a structured framework for selling shares over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/19/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last)

(First)

(Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND

98033

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	02/17/2026	02/17/2026	S⁽¹⁾		11,635	D	$25.3937⁽²⁾	383,151	D
Common Shares	02/17/2026	02/17/2026	S⁽¹⁾		3,272	D	$26.2947⁽³⁾	379,879	D
Common Shares	02/17/2026	02/17/2026	S⁽¹⁾		93	D	$27.1789⁽⁴⁾	379,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0150 to $26.0100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.0200 to $26.9998. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.0771 to $27.1800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR